Table 4.
Relationships of clinical manifestations to C. trachomatis genotypes in 283 women infected with single-genotype of C. trachomatis.
| Manifestations | C. trachomatis genotype (n = 261)a | C. trachomatis genogroup (n = 283) | ||||||
|---|---|---|---|---|---|---|---|---|
| E n = 83 | D n = 40 | F n = 65 | G n = 18 | J n = 55 | B-complex n = 125 | F/G group n = 83 | C-complex n = 75 | |
| Asymptomatic | ||||||||
| Yes (n, %) | 22 (26.5) | 15 (37.5) | 20 (30.8) | 6 (33.3) | 13 (23.6) | 37 (29.6) | 26 (31.3) | 20 (26.7) |
| OR (95% CI)b | Refc | 1.58 (0.56–4.51) | 0.81 (0.33–1.99) | 0.69 (0.18–2.67) | 0.78 (0.3–2.05) | Ref | 0.7 (0.33–1.51) | 0.91 (0.42–2.0) |
| Vaginosis | ||||||||
| Yes (n, %) | 33 (39.8) | 14 (35.0) | 20 (30.8) | 5 (27.8) | 28 (50.9) | 48 (38.4) | 25 (30.1) | 35 (46.7) |
| OR (95% CI) | Ref | 0.87 (0.37–2.06) | 0.79 (0.38–1.64) | 0.73 (0.22–2.42) | 1.75 (0.84–3.66) | Ref | 0.8 (0.43–1.51) | 1.43 (0.77–2.66) |
| Pelvic inflammatory disease | ||||||||
| Yes (n, %) | 8 (9.6) | 2 (5.0) | 7 (10.8) | 5 (27.8) | 9 (16.4) | 10 (8.0) | 12 (14.5) | 10 (13.3) |
| OR (95% CI) | Ref | 0.32 (0.04–2.41) | 1.44 (0.42–4.9) | 6.06 (1.29–28.5) | 1.54 (0.48–4.91) | Ref | 2.71 (0.95–7.78) | 1.49 (0.52–4.3) |
| Cervicitis | ||||||||
| Yes (n, %) | 5 (6.0) | 4 (10.0) | 8 (12.3) | 2 (11.1) | 3 (5.5) | 9 (7.2) | 10 (12.0) | 5 (6.7) |
| OR (95% CI) | Ref | 1.71 (0.41–7.05) | 2.07 (0.63–6.86) | 1.88 (0.32–10.9) | 0.89 (0.2–3.94) | Ref | 1.62 (0.61–4.32) | 0.92 (0.29–2.94) |
| Vagina cleanliness (vs. I/II) | ||||||||
| III (n, %) | 16 (29.1) | 9 (36.0) | 17 (37.8) | 6 (40.0) | 18 (45.0) | 26 (31.7) | 23 (38.3) | 21 (39.6) |
| OR (95% CI) | Ref | 1.71 (0.52–5.58) | 1.43 (0.56–3.67) | 3.16 (0.65–15.32) | 2.39 (0.88–6.49) | Ref | 1.39 (0.62–3.14) | 1.48 (0.64–3.45) |
| IV (n, %) | 15 (27.3) | 7 (28.0) | 9 (20.0) | 6 (40.0) | 10 (25.0) | 22 (26.8) | 15 (25.0) | 14 (26.4) |
| OR (95% CI) | Ref | 2.49 (0.6–10.29) | 0.89 (0.28–2.87) | 6.91 (1.25–38.09) | 1.59 (0.49–5.12) | Ref | 1.29 (0.49–3.38) | 1.18 (0.44–3.15) |
| Cervical abnormalities (vs. Benign)d | ||||||||
| ASC-US (n, %) | 4 (6.0) | 2 (5.7) | 1 (1.8) | 0 | 3 (7.7) | 6 (5.8) | 1 (1.4) | 6 (10.7) |
| OR (95% CI) | Ref | 0.71 (0.11–4.77) | 0.32 (0.03–3.42) | NAe | 0.84 (0.15–4.73) | Ref | 0.31 (0.04–2.81) | 1.79 (0.5–6.48) |
| SIL (n, %) | 4 (6.0) | 6 (17.1) | 9 (16.4) | 1 (6.7) | 4 (10.3) | 10 (9.6) | 10 (14.3) | 6 (10.7) |
| OR (95% CI) | Ref | 2.96 (0.71–12.34) | 3.44 (0.94–12.58) | 1.15 (0.11–11.98) | 1.67 (0.38–7.41) | Ref | 1.82 (0.68–4.88) | 1.21 (0.4–3.69) |
aGenotypes of < 5% of the total patients were analyzed only in their corresponding genogroups.bOdds ratio (OR) was calculated in multivariate logistic regression analysis in which the parameters of age, clinical departments, antibiotic usage and HPV infection were under control. Bold OR and aOR indicate statistically significant, i.e., p < 0.05.cGenotype E and B-complex genogroup were set as reference group, respectively.dASC-US, atypical squamous cells of undetermined significance; SIL, squamous intraepithelial lesion.eNA, not applicable.